PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer: Do we know how to use it?
- 30 April 1998
- journal article
- review article
- Published by Elsevier in Seminars in Radiation Oncology
- Vol. 8 (2), 72-80
- https://doi.org/10.1016/s1053-4296(98)80002-7
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- An enhanced prognostic system for clinically localized carcinoma of the prostateCancer, 1997
- Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional updatePublished by American Medical Association (AMA) ,1997
- Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1995
- Prostate-specific antigen and radiation therapy for clinically localized prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1995
- Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis.Journal of Clinical Oncology, 1995
- Radical Radiation Therapy in the Management of Prostatic Adenocarcinoma: The Initial Prostate Specific Antigen Value as a Predictor of Treatment OutcomeJournal of Urology, 1994
- How to use prostate-specific antigenUrology, 1994
- Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and gleason score in men with clinically localized prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Re: The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate Cancer, by A. W. Partin, J. Yoo, H. B. Carter, J. D. Pearson, D. W. Chan, J. I. Epstein and P. C. Walsh, J. Urol., 150: 110-114, 1993Journal of Urology, 1993
- Prostate Specific Antigen: A Critical Assessment of the Most Useful Tumor Marker for Adenocarcinoma of the ProstateJournal of Urology, 1991